CTN Dissemination Library

  • Browse & Search
    • Search the CTN Library
    • In press articles
    • Search the site/blog
  • Nodes
  • Protocols
  • Training
    • CTN & Other Training
    • Upcoming Events
  • Resources
    • What’s New Blog
    • NIDA CTN Site
    • CTN Bulletin
    • CTN Common Data Elements (CDE)
    • CTN Directory (2025)
    • PATHS Toolkit
    • Implementation
    • General Resources
  • About Us
  • Browse & Search
    • Search the CTN Library
    • In press articles
    • Search the site/blog
  • Nodes
  • Protocols
  • Training
    • CTN & Other Training
    • Upcoming Events
  • Resources
    • What’s New Blog
    • NIDA CTN Site
    • CTN Bulletin
    • CTN Common Data Elements (CDE)
    • CTN Directory (2025)
    • PATHS Toolkit
    • Implementation
    • General Resources
  • About Us
  • Discriminative validity of a substance use symptom checklist for moderate-severe DSM-5 cannabis use disorder (CUD) in primary care settings.

    Hamilton LK, Bradley KA, Matson TE, Lapham GT. Discriminative validity of a substance use symptom checklist for moderate-severe DSM-5 cannabis use disorder (CUD) in primary care settings. Drug and Alcohol Dependence Reports 2024;12:100260.

    Read More
  • Predictors of urine toxicology and other biologic specimen missingness in randomized trials of substance use disorders.

    Kelley AT, Incze MA, Baumgartner M, Campbell ANC, Nunes EV, Scharfstein DO. Predictors of urine toxicology and other biologic specimen missingness in randomized trials of substance use disorders. Drug and Alcohol Dependence 2024;261:111368.

    Read More
  • Extended-release 7-day injectable buprenorphine for patients with minimal to mild opioid withdrawal.

    D'Onofrio G, Herring AA, Perrone J, Hawk K, Samuels EA, Cowan E, Anderson E, McCormack R, Huntley K, Owens P, Martel S, Schactman M, Lofwall MR, Walsh SL, Dziura J, Fiellin DA. Extended-release 7-day injectable buprenorphine for patients with minimal to mild opioid withdrawal. JAMA Network Open 2024;7(7):e2420702.

    Read More
  • Barriers and facilitators to using a clinical decision support tool for opioid use disorder in primary care: Insights from clinicians and clinic leaders.

    Hooker SA, Solberg LI, Miley KM, Borgert-Spaniol C, Rossom RC. Barriers and facilitators to using a clinical decision support tool for opioid use disorder in primary care: Insights from clinicians and clinic leaders. Journal of the American Board of Family Medicine 2024;37(3):389-398.

    Read More
  • Assessing substance use disorder symptoms with a checklist among primary care patients with opioid use disorder and/or long-term opioid treatment: An observational study.

    Williams EC, Matson TE, Hallgren KA, Oliver M, Wang X, Bradley KA. Assessing substance use disorder symptoms with a checklist among primary care patients with opioid use disorder and/or long-term opioid treatment: An observational study. Journal of General Internal Medicine 2024;39:2169-2178.

    Read More
  • Predictability of buprenorphine-naloxone treatment retention: A multi-site analysis combining electronic health records and machine learning.

    Haredasht FN, Fouladvand S, Tate S, Chan MM, Yeow JJL, Griffiths K, Lopez I, Bertz JW, Miner AS, Hernandez-Boussard T, Chen CA, Den H, Humphreys K, Lembke A, Vance LA, Chen JH. Predictability of buprenorphine-naloxone treatment retention: A multi-site analysis combining electronic health records and machine learning. Addiction 2024;119(10):1792-1802.

    Read More
  • “To prescribe or not to prescribe, that is the question:” Perspectives on opioid prescribing for chronic, cancer-related pain from clinicians who treat pain in survivorship.

    Bulls HW, Hamm M, Wasilewski J, Olejniczak D, Bell SG, Liebschutz JM. "To prescribe or not to prescribe, that is the question": Perspectives on opioid prescribing for chronic, cancer-related pain from clinicians who treat pain in survivorship. Cancer 2024;130(17):3034-3042.

    Read More
  • Discontinuation of medication treatment for opioid use disorder after a successful course: The discontinuation phase of the CTN-0100 (RDD) trial.

    Shulman M, Provost SE, Ohrtman K, Novo P, Meyers-Ohki S, VanVeldhuisen PC, Oden N, Otterstatter M, Bailey GL, Liu D, Rotrosen J, Nunes EV, Weiss RD. Discontinuation of medication treatment for opioid use disorder after a successful course: The discontinuation phase of the CTN-0100 (RDD) trial. Contemporary Clinical Trials 2024;142:107543.

    Read More
  • Wiidookaage’win: Beta-test of a Facebook group intervention for Native women to support opioid use recovery.

    Roche AI, Young A, Sabaque C, Kelpin SS, Sinicrope P, Pham C, Marsch LA, Campbell ANC, Venner KL, Baker-DeKrey L, Wyatt T, WhiteHawk S, Nord T, Resnicow K, Young C, Brown A, Bart G, Patten C. Wiidookaage'win: Beta-test of a Facebook group intervention for Native women to support opioid use recovery. Journal of Substance Use and Addiction Treatment 2024;163:209396.

    Read More
  • Wiidookaage’Win: A community-based qualitative approach to developing a Facebook group intervention for Native women to support recovery from opioid use.

    Young A, Sinicrope P, Kelpin S, Roche AI, Sabaque C, Pham C, Marsch LA, Campbell ANC, Venner KL, Bastian E, Nord T, Mason G, Baker L, Wyatt T, Fish A, Bart G, Patten C. Wiidookaage'Win: A community-based qualitative approach to developing a Facebook group intervention for Native women to support recovery from opioid use. American Journal of Health Promotion 2024;38(2):205-218.

    Read More
910111213

Recent Posts

  • Now in the CTN Library: NIDA CTN Common Data Elements
  • New in the Library (March – April 2026)
  • CTN Primary Care SIG Webinar: Conducting Substance Use Research in Prison (March 23, 2026, 12pm ET)
  • New in the Library (February – March 2026)
  • News from the Appalachian Node: Brief Report for CTN-0135 Published

Recent Comments

No comments to show.

Archives

  • April 2026
  • March 2026
  • February 2026
  • January 2026
  • December 2025
  • November 2025
  • October 2025
  • September 2025
  • August 2025
  • July 2025
  • June 2025
  • May 2025
  • April 2025
  • March 2025
  • February 2025
  • January 2025
  • December 2024
  • November 2024
  • October 2024
  • September 2024
  • August 2024
  • July 2024
  • June 2024
  • May 2024
  • April 2024
  • March 2024
  • February 2024
  • January 2024
  • December 2023
  • November 2023
  • October 2023
  • September 2023
  • August 2023
  • July 2023
  • June 2023
  • May 2023
  • April 2023
  • March 2023
  • February 2023
  • January 2023
  • December 2022
  • September 2022

Categories

  • DSC News
  • Events
  • Funding
  • Jobs
  • New in the Library
  • Node News
  • Other
  • Protocol News
  • SIG Updates
  • Uncategorized
Supported by a grant from the National Institute on Drug Abuse to the University of Washington Department of Psychiatry & Behavioral Science's Addictions, Drug & Alcohol Institute (ADAI). The materials on this site have neither been created nor reviewed by NIDA.